These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1194 related articles for article (PubMed ID: 28954437)

  • 1. Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals.
    Della Pepa G; Vetrani C; Lombardi G; Bozzetto L; Annuzzi G; Rivellese AA
    Nutrients; 2017 Sep; 9(10):. PubMed ID: 28954437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease.
    Eslamparast T; Tandon P; Raman M
    Nutrients; 2017 Jul; 9(8):. PubMed ID: 28933748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of diet and nutritional management in non-alcoholic fatty liver disease.
    Fan JG; Cao HX
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():81-7. PubMed ID: 24251710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance.
    Yki-Järvinen H
    Nutrients; 2015 Nov; 7(11):9127-38. PubMed ID: 26556368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.
    Hydes TJ; Summers N; Brown E; Alam U; Thomaides-Brears H; Wilding JPH; Cuthbertson DJ
    Diabet Med; 2020 Nov; 37(11):1793-1806. PubMed ID: 32619031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?
    Firneisz G
    World J Gastroenterol; 2014 Jul; 20(27):9072-89. PubMed ID: 25083080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
    Satapathy SK; Sanyal AJ
    Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.
    Milić S; Lulić D; Štimac D
    World J Gastroenterol; 2014 Jul; 20(28):9330-7. PubMed ID: 25071327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early life programming and the risk of non-alcoholic fatty liver disease.
    Lynch C; Chan CS; Drake AJ
    J Dev Orig Health Dis; 2017 Jun; 8(3):263-272. PubMed ID: 28112071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
    Stefan N; Häring HU; Cusi K
    Lancet Diabetes Endocrinol; 2019 Apr; 7(4):313-324. PubMed ID: 30174213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms.
    Zelber-Sagi S; Salomone F; Mlynarsky L
    Liver Int; 2017 Jul; 37(7):936-949. PubMed ID: 28371239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health benefits of Mediterranean diet in nonalcoholic fatty liver disease.
    Abenavoli L; Di Renzo L; Boccuto L; Alwardat N; Gratteri S; De Lorenzo A
    Expert Rev Gastroenterol Hepatol; 2018 Sep; 12(9):873-881. PubMed ID: 30033779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease and cardiovascular disease.
    Hyogo H; Chayama K; Yamagishi S
    Curr Pharm Des; 2014; 20(14):2403-11. PubMed ID: 23844815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease.
    Rix I; Steen Pedersen J; Storgaard H; Gluud LL
    Clin Physiol Funct Imaging; 2019 Mar; 39(2):122-127. PubMed ID: 29808958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander.
    Vanni E; Marengo A; Mezzabotta L; Bugianesi E
    Semin Liver Dis; 2015 Aug; 35(3):236-49. PubMed ID: 26378641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the association between developing a fatty liver and subsequent cardio-metabolic complications.
    Miele L; Targher G
    Expert Rev Gastroenterol Hepatol; 2015; 9(10):1243-5. PubMed ID: 26224399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.